Resmetirom, sold under the brand name Rezdiffra, is a medication used to treat a form of fatty liver disease. Specifically it is used in the treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) (formerly known as nonalcoholic steatohepatitis NASH). It is structurally similar to the thyroid hormone triiodothyronine and acts as an agonist of the thyroid hormone receptor beta (NR1A2).<\/p>\n
The most common side effects include diarrhea and nausea.<\/p>\n
NASH is a result of the progression of nonalcoholic fatty liver disease where liver inflammation, over time, can lead to liver scarring and liver dysfunction. NASH is often associated with other health problems such as high blood pressure and type 2 diabetes. By at least one estimate, approximately 6-8 million people in the U.S. have NASH with moderate to advanced liver scarring, with that number expected to increase. Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation.<\/p>\n
REZDIFFRA (resmetirom) tablets, for oral use Initial U.S. Approval: 2024 <\/strong><\/p>\n REZDIFFRA (resmetirom) may be accessed in India through a named-patient import process<\/strong>\u00a0with a valid doctor\u2019s prescription, and\u00a0Indian Pharma Network (IPN), New Delhi, assists with compliant sourcing<\/strong>\u00a0and delivery of specialty medicines subject to regulatory approvals.<\/p>\n Indian Pharma Network (IPN), based in New Delhi, helps patients and healthcare providers with the sourcing and import coordination of specialty medicines in compliance with applicable Indian regulations.<\/strong>\u00a0Availability, import eligibility, pricing, and delivery timelines may vary and are subject to regulatory approvals and documentation requirements.<\/p>\n IPN having representation in<\/strong>\u00a0Delhi, Gurugram, Mumbai, Bengaluru, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur, and Lucknow.<\/p>\n Named-patient import facilitator contact details<\/strong> Patients are advised to independently verify the credentials, licensing, and regulatory compliance of any facilitator before proceeding.<\/em><\/p>\n NEWS\/UPDATES<\/p>\n Note:<\/strong><\/em> Rezdiffra (resmetirom) is the first FDA-approved medication for adults with metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) who have moderate to advanced liver scarring (fibrosis), used alongside diet and exercise to reduce liver fat, inflammation, and scarring by targeting liver thyroid hormone receptors. It’s an oral tablet taken once daily and works as a liver-directed therapy, though potential side effects include diarrhea, nausea, itching, and gallbladder issues, with ongoing studies confirming its long-term benefits.<\/p>\nIs REZDIFFRA (resmetirom) available in India?<\/h4>\n
How to get REZDIFFRA Tablets delivered in India?<\/h4>\n
Who can help source REZDIFFRA Tablets in India legally?<\/h4>\n
\nCompany Name:<\/strong>\u00a0Indian Pharma Network (IPN)
\nAddress:<\/strong>\u00a060\/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016
\nFor sourcing and import coordination of specialty medicines, contact:<\/strong>
\nMr. Tarun:<\/strong>\u00a0+91 9891 296 838
\nMr. Neeraj:<\/strong>\u00a0+91 9811 747 774
\nEmail:\u00a0info@indianpharmanetwork.co.in<\/a><\/strong><\/p>\n\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.\u00a0Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a>. With over two decades of industry experience, IPN offers extensive coverage across India.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"REZDIFFRA (resmetirom) \u2013 MASH, formerly NASH Therapy in India<\/h2>\n
\n\n
\n Brand Name:<\/strong><\/td>\n REZDIFFRA<\/td>\n<\/tr>\n \n Generic Name:<\/strong><\/td>\n Resmetirom Tablets<\/td>\n<\/tr>\n \n Strength:<\/strong><\/td>\n \u2022 Tablets: 60 mg, 80 mg, and 100 mg<\/td>\n<\/tr>\n \n Manufacturer:<\/strong><\/td>\n Madrigal Pharmaceuticals<\/td>\n<\/tr>\n \n Approved By:<\/strong><\/td>\n EMA, USFDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n